JP2017520571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520571A5 JP2017520571A5 JP2016575155A JP2016575155A JP2017520571A5 JP 2017520571 A5 JP2017520571 A5 JP 2017520571A5 JP 2016575155 A JP2016575155 A JP 2016575155A JP 2016575155 A JP2016575155 A JP 2016575155A JP 2017520571 A5 JP2017520571 A5 JP 2017520571A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- surgery
- syndrome
- eye
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 34
- 238000001356 surgical procedure Methods 0.000 claims 31
- 208000035475 disorder Diseases 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 210000004185 liver Anatomy 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 239000012825 JNK inhibitor Substances 0.000 claims 9
- 229940118135 JNK inhibitor Drugs 0.000 claims 9
- 208000007287 cheilitis Diseases 0.000 claims 9
- 201000004328 Pulpitis Diseases 0.000 claims 8
- 206010037464 Pulpitis dental Diseases 0.000 claims 8
- 201000001245 periodontitis Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 208000017442 Retinal disease Diseases 0.000 claims 7
- 206010038923 Retinopathy Diseases 0.000 claims 7
- 208000007565 gingivitis Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 208000003265 stomatitis Diseases 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 4
- 206010028116 Mucosal inflammation Diseases 0.000 claims 4
- 201000010927 Mucositis Diseases 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 210000002216 heart Anatomy 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 208000002177 Cataract Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010034038 Parotitis Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000002399 aphthous stomatitis Diseases 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 210000000936 intestine Anatomy 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 230000000306 recurrent effect Effects 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 2
- 206010073360 Appendix cancer Diseases 0.000 claims 2
- 208000006478 Cecal Neoplasms Diseases 0.000 claims 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 2
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000006389 Peri-Implantitis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 208000009125 Sigmoid Neoplasms Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000010838 ascending colon cancer Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000003959 cecum carcinoma Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 210000004087 cornea Anatomy 0.000 claims 2
- 238000002316 cosmetic surgery Methods 0.000 claims 2
- 201000003823 descending colon cancer Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 210000003709 heart valve Anatomy 0.000 claims 2
- 208000006359 hepatoblastoma Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 201000006334 interstitial nephritis Diseases 0.000 claims 2
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 210000001331 nose Anatomy 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000003825 sigmoid colon cancer Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 201000010986 transverse colon cancer Diseases 0.000 claims 2
- 208000030954 urea cycle disease Diseases 0.000 claims 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010010252 Concentric sclerosis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 208000031994 Cutaneous small vessel vasculitis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000006819 Denture Stomatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000029470 Hughes-Stovin syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000005995 Lichenoid Eruptions Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000030162 Maple syrup disease Diseases 0.000 claims 1
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims 1
- 206010072654 Medium-chain acyl-coenzyme A dehydrogenase deficiency Diseases 0.000 claims 1
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010028034 Mouth ulceration Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 208000006595 Necrotizing Ulcerative Gingivitis Diseases 0.000 claims 1
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 208000033716 Organic aciduria Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000011252 Phenylketonuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 206010036182 Porphyria acute Diseases 0.000 claims 1
- 208000016855 Porphyrin metabolism disease Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 claims 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010040844 Skin exfoliation Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000002286 Susac Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 208000033608 aggressive 1 periodontitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 230000037354 amino acid metabolism Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000019493 atypical carcinoid tumor Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 claims 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000020670 canker sore Diseases 0.000 claims 1
- 208000022843 carbamoyl phosphate synthetase I deficiency disease Diseases 0.000 claims 1
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000019884 chronic gingivitis Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000001277 chronic periodontitis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 238000005336 cracking Methods 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 238000004299 exfoliation Methods 0.000 claims 1
- 208000002980 facial hemiatrophy Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000010995 liver angiosarcoma Diseases 0.000 claims 1
- 208000024393 maple syrup urine disease Diseases 0.000 claims 1
- 210000001370 mediastinum Anatomy 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 230000006677 mitochondrial metabolism Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 201000008152 organic acidemia Diseases 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000004480 periapical periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000002824 peroxisome Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 230000004144 purine metabolism Effects 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 230000004147 pyrimidine metabolism Effects 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000000574 retroperitoneal space Anatomy 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 206010040400 serum sickness Diseases 0.000 claims 1
- 210000002832 shoulder Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 201000003824 splenic flexure cancer Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000037359 steroid metabolism Effects 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 201000008587 ulcerative stomatitis Diseases 0.000 claims 1
- 208000005925 vesicular stomatitis Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/001881 WO2014206427A1 (en) | 2013-06-26 | 2013-06-26 | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EP2013001896 | 2013-06-27 | ||
| PCT/EP2014/001736 WO2014206563A2 (en) | 2013-06-26 | 2014-06-26 | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EPPCT/EP2014/001736 | 2014-06-26 | ||
| EPPCT/EP2014/002724 | 2014-10-08 | ||
| PCT/EP2014/002724 WO2015197098A1 (en) | 2014-06-26 | 2014-10-08 | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| PCT/EP2015/001294 WO2015197194A2 (en) | 2014-06-26 | 2015-06-26 | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005107A Division JP7165693B2 (ja) | 2014-06-26 | 2020-01-16 | 様々な疾患の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017520571A JP2017520571A (ja) | 2017-07-27 |
| JP2017520571A5 true JP2017520571A5 (enExample) | 2018-07-26 |
Family
ID=51033122
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522321A Withdrawn JP2016523274A (ja) | 2013-06-26 | 2014-06-26 | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 |
| JP2016575155A Withdrawn JP2017520571A (ja) | 2013-06-26 | 2015-06-26 | 様々な疾患の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用 |
| JP2019226998A Pending JP2020055866A (ja) | 2013-06-26 | 2019-12-17 | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522321A Withdrawn JP2016523274A (ja) | 2013-06-26 | 2014-06-26 | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019226998A Pending JP2020055866A (ja) | 2013-06-26 | 2019-12-17 | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10624948B2 (enExample) |
| EP (1) | EP3013353B1 (enExample) |
| JP (3) | JP2016523274A (enExample) |
| KR (1) | KR20160023669A (enExample) |
| CN (1) | CN105307670A (enExample) |
| AU (1) | AU2014301631A1 (enExample) |
| BR (1) | BR112016029413A2 (enExample) |
| CA (1) | CA2903275A1 (enExample) |
| EA (1) | EA201501080A1 (enExample) |
| ES (1) | ES2870085T3 (enExample) |
| HK (1) | HK1224225A1 (enExample) |
| MX (1) | MX2016017308A (enExample) |
| PL (1) | PL3013353T3 (enExample) |
| WO (1) | WO2014206563A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| US10624948B2 (en) | 2013-06-26 | 2020-04-21 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EP3936141A3 (en) * | 2015-01-23 | 2022-03-23 | Erasmus University Rotterdam Medical Center | Anti-senescence compounds and uses thereof |
| CN109303782A (zh) * | 2018-10-24 | 2019-02-05 | 厦门大学 | Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用 |
| WO2021046652A1 (en) | 2019-09-12 | 2021-03-18 | The University Of British Columbia | Inhibiting zd17-jnk interaction as a therapy for acute myocardial infarction |
| KR102151133B1 (ko) * | 2019-12-27 | 2020-09-02 | 주식회사 인투앱 | 프로피오니박테리움 아크네스에 특이적으로 결합하는 신규한 항체 및 이의 용도 |
| WO2022009698A1 (ja) * | 2020-07-06 | 2022-01-13 | 学校法人東京薬科大学 | ペプチドおよびそれを含む複合体 |
| KR102273163B1 (ko) * | 2020-09-10 | 2021-07-05 | 주식회사 파이안바이오테크놀로지 | 혈소판 유래 미토콘드리아의 수득 방법 및 이의 용도 |
| CN113633662B (zh) * | 2021-07-02 | 2023-09-26 | 中山大学附属口腔医院 | 线粒体移植在治疗牙周炎中的应用 |
| CN117147251B (zh) * | 2023-08-16 | 2024-04-26 | 四川大学 | 一种人类离体牙髓组织透明化方法 |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1195304B (it) | 1981-12-22 | 1988-10-12 | Anic Spa | Metodo per la preparazione di gem-diammino derivati n-monoacilati |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| IT1190389B (it) | 1985-09-19 | 1988-02-16 | Eniricerche Spa | Esapeptidi ad attivita' ipotensiva |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| IT1227907B (it) | 1988-12-23 | 1991-05-14 | Eniricerche S P A Milano Sclav | Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
| US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
| WO1992018138A1 (en) | 1991-04-10 | 1992-10-29 | The General Hospital Corporation | Mammalian gap-43 compositions and methods of use |
| US5994108A (en) | 1991-11-05 | 1999-11-30 | Board Of Regents, The University Of Texas System | Mutant TAR virus and transdominant tat mutants as pharmacological agents |
| US5350835A (en) | 1991-11-05 | 1994-09-27 | Board Of Regents, University Of Texas | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids |
| EP0632722A4 (en) | 1992-03-20 | 1997-07-30 | Baylor College Medicine | DNA TRANSPORTATION SYSTEM AND INSTRUCTIONS FOR USE. |
| JP4074658B2 (ja) | 1992-04-03 | 2008-04-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 自己構築ポリヌクレオチド送達システム |
| WO1994004562A1 (en) | 1992-08-13 | 1994-03-03 | The General Hospital Corporation | Mammalian gap-43 compositions and methods of use |
| EP0656950B1 (en) * | 1992-08-21 | 1998-11-04 | Biogen, Inc. | Tat-derived transport polypeptides |
| EP0667786B1 (en) | 1992-08-27 | 2004-01-21 | Deakin Research Limited | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
| US5545551A (en) | 1992-08-28 | 1996-08-13 | Mt. Sinai School Of Medicine Of The City University Of New York | Cloning and expression of pur protein |
| EP0693939A1 (de) | 1993-04-14 | 1996-01-31 | Roche Diagnostics GmbH | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen |
| EP0679716A4 (en) | 1993-11-12 | 1999-06-09 | Kenichi Matsubara | GENE SIGNATURE. |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| EP0767833A1 (en) | 1995-04-25 | 1997-04-16 | Baxter International Inc. | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells |
| CA2227786A1 (en) | 1995-07-28 | 1997-02-13 | Marie Curie Cancer Care | Transport proteins and their uses |
| AU7366896A (en) | 1995-09-21 | 1997-04-09 | Innapharma, Inc. | Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras |
| IE80466B1 (en) | 1995-11-10 | 1998-07-29 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| US6630351B1 (en) | 1999-06-07 | 2003-10-07 | Mirus Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US5877282A (en) | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| US6187817B1 (en) | 1996-10-03 | 2001-02-13 | Southern Illinois University School Of Medicine | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| WO1998023781A1 (en) | 1996-11-26 | 1998-06-04 | Johns Hopkins University | Ligand detection system and methods of use thereof |
| US5989814A (en) | 1997-04-01 | 1999-11-23 | Reagents Of The University Of California | Screening methods in eucaryotic cells |
| US5880261A (en) | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
| AU6972798A (en) | 1997-04-18 | 1998-11-13 | University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
| US6043083A (en) | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
| JP4129298B2 (ja) | 1997-05-15 | 2008-08-06 | サイトジェン コーポレーション | 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法 |
| IL132941A0 (en) | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| FR2767323B1 (fr) | 1997-08-12 | 2001-01-05 | Synt Em | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
| EP0897002A3 (en) | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
| WO1999016787A1 (en) | 1997-09-26 | 1999-04-08 | Washington University | Cell death agonists |
| US6420031B1 (en) | 1997-11-03 | 2002-07-16 | The Trustees Of Princeton University | Highly transparent non-metallic cathodes |
| AU745579B2 (en) * | 1997-10-20 | 2002-03-21 | F. Hoffmann-La Roche Ag | Bicyclic kinase inhibitors |
| US6270956B1 (en) | 1997-12-11 | 2001-08-07 | The Salk Institute For Biological Studies | Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor |
| EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| CA2330458A1 (en) | 1998-04-29 | 1999-11-04 | Georgetown University | Methods of identifying and using hla binding compounds as hla-agonists and antagonists |
| EP1076711A2 (en) | 1998-05-13 | 2001-02-21 | Incyte Pharmaceuticals, Inc. | Human apoptosis associated proteins |
| US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| WO1999058561A1 (fr) | 1998-05-14 | 1999-11-18 | Pasteur Merieux Serums & Vaccins | Mimotopes du virus de l'hepatite c |
| US6740524B1 (en) | 1998-06-18 | 2004-05-25 | Dnavec Research, Inc. | Nucleic acid transfer phage |
| AU755564B2 (en) | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| EP1107998B1 (en) | 1998-08-28 | 2004-02-04 | Gryphon Sciences | Method for the preparation of polyamide chains of precise length, their conjugates with proteins |
| JP2002525329A (ja) | 1998-09-25 | 2002-08-13 | セフアロン・インコーポレーテツド | 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する／処置するための方法 |
| US20020090696A1 (en) | 1998-12-08 | 2002-07-11 | Miller Carol A. | Treating neurological disorders using human apoptosis inhibiting protein |
| US6656474B1 (en) | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| JP2003506071A (ja) | 1999-05-28 | 2003-02-18 | アポプトシス テクノロジー，アイエヌシー． | アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法 |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| AU5316900A (en) | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| EP2269654A3 (en) | 1999-08-24 | 2011-04-13 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| EP1210362A2 (en) | 1999-09-01 | 2002-06-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| US20030108539A1 (en) | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US6610820B1 (en) | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20010046489A1 (en) | 1999-12-06 | 2001-11-29 | Habener Joel E. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| EP1242118B1 (en) | 1999-12-16 | 2009-11-11 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| ATE508138T1 (de) | 2000-06-16 | 2011-05-15 | Serodus As | N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide |
| US6586403B1 (en) | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| EP1345956A2 (en) | 2000-10-13 | 2003-09-24 | University of Lausanne | Intracellular delivery of biological effectors by novel transporter peptide sequences |
| US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
| ES2386505T3 (es) | 2000-10-17 | 2012-08-22 | Diatranz Otsuka Limited | Preparación y xenotrasplante de islotes de cerdo |
| US20030077826A1 (en) | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
| MXPA03007358A (es) | 2001-02-16 | 2004-12-13 | Cellgate Inc | Transportadores que contienen porciones de arginina separadas. |
| JP4234999B2 (ja) | 2001-04-06 | 2009-03-04 | トマス ジェファソン ユニバーシティ | 治療標的としてのｈｉｖ−１ｖｉｆタンパク質の多量体形成 |
| DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| AU2002322519A1 (en) | 2001-07-17 | 2003-03-03 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
| AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| US7635681B2 (en) | 2002-01-09 | 2009-12-22 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
| US20040034084A1 (en) * | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
| CA2488013A1 (en) * | 2002-05-30 | 2003-12-11 | Celgene Corporation | Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| JP2004066595A (ja) | 2002-08-05 | 2004-03-04 | Canon Finetech Inc | 記録装置およびレジストレーション用パターンの記録方法 |
| JP2006502183A (ja) | 2002-09-20 | 2006-01-19 | アルコン，インコーポレイテッド | ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用 |
| EP1408114B1 (de) | 2002-10-11 | 2007-01-03 | Imvision GmbH | Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen |
| US20040186052A1 (en) * | 2002-10-24 | 2004-09-23 | Suhasini Iyer | Cytomodulating peptides and methods for treating neurological disorders |
| ZA200503242B (en) * | 2002-10-24 | 2006-10-25 | Celgene Corp | Treatment of pain with JNK inhibitors |
| US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
| JP4787150B2 (ja) | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｊｎｋ阻害剤 |
| CA2523672C (en) | 2003-04-29 | 2012-07-17 | Avi Biopharma, Inc. | Compositions for enhancing transport of molecules into cells |
| US20050048995A1 (en) | 2003-08-25 | 2005-03-03 | Motorola, Inc. | System and method for controlling the operating characteristics of a buffer |
| KR100685345B1 (ko) | 2004-03-27 | 2007-02-22 | 학교법인조선대학교 | 세포사 유도 펩타이드 |
| AU2005230416B2 (en) | 2004-04-08 | 2010-05-13 | Merck Serono Sa | Composition comprising a JNK inhibitor and cyclosporin |
| WO2006021458A2 (en) * | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
| US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
| EP1656951A1 (en) | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| US20100256041A1 (en) | 2004-11-12 | 2010-10-07 | Christophe Bonny | Conjugate Molecule Compounds With Enhanced Cell Uptake Activity |
| EP1661912A1 (en) | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| ZA200706662B (en) * | 2005-01-13 | 2009-04-29 | Signal Pharmaceiticals Llc | Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| CA2606110A1 (en) | 2005-04-29 | 2006-12-07 | Celgene Corporation | Solid forms of 1-(5-(1h-1,2,4-triazol-5-yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene |
| US20070015779A1 (en) | 2005-04-29 | 2007-01-18 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US10045953B2 (en) | 2006-07-06 | 2018-08-14 | Case Western Reserve University | Ceramide composition and method of use |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| WO2008094208A2 (en) * | 2006-08-02 | 2008-08-07 | Northwestern University | Protein kinase targeted therapeutics |
| JP5325783B2 (ja) | 2006-09-08 | 2013-10-23 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾトリアゾールキナーゼモジュレーター |
| EP2074138A4 (en) | 2006-09-19 | 2009-12-30 | Phylogica Ltd | NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF |
| GB0702259D0 (en) * | 2007-02-06 | 2007-03-14 | Eisai London Res Lab Ltd | 7-azaindole derivatives |
| DK2282779T3 (da) | 2008-04-29 | 2013-05-27 | Pharnext | Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons |
| CN105664136A (zh) | 2008-05-07 | 2016-06-15 | 加利福尼亚大学董事会 | 眼表润滑的治疗性补充和富集 |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| US20100183633A1 (en) | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| EP2381934A2 (en) | 2008-12-23 | 2011-11-02 | Carmel - Haifa University Economic Corp Ltd. | Improving cognitive function |
| US8450363B2 (en) * | 2009-02-06 | 2013-05-28 | Elan Pharmaceuticals, Inc. | Inhibitors of Jun N-terminal kinase |
| JP2010254672A (ja) * | 2009-03-30 | 2010-11-11 | Santen Pharmaceut Co Ltd | ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤 |
| JP5784604B2 (ja) * | 2009-08-10 | 2015-09-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊｎｋ阻害剤 |
| RU2012120783A (ru) | 2009-10-22 | 2013-11-27 | Женентек, Инк. | Модуляция дегенерации аксона |
| US20130190244A1 (en) | 2009-12-31 | 2013-07-25 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| RU2012155144A (ru) * | 2010-06-04 | 2014-07-20 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы jnk |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| PL2902035T3 (pl) | 2010-10-14 | 2019-04-30 | Xigen Inflammation Ltd | Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka |
| US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
| WO2013079213A1 (en) | 2011-11-30 | 2013-06-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
| WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2014206426A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| US10624948B2 (en) | 2013-06-26 | 2020-04-21 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| JP2015197193A (ja) | 2014-04-02 | 2015-11-09 | トヨタ自動車株式会社 | 車両用無段変速機の油圧制御装置 |
| EP3160989A2 (en) | 2014-06-26 | 2017-05-03 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| US20180170983A1 (en) | 2015-06-26 | 2018-06-21 | Xigen Inflammation Ltd. | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment |
-
2014
- 2014-06-26 US US14/891,067 patent/US10624948B2/en active Active
- 2014-06-26 CA CA2903275A patent/CA2903275A1/en not_active Abandoned
- 2014-06-26 JP JP2016522321A patent/JP2016523274A/ja not_active Withdrawn
- 2014-06-26 KR KR1020157034160A patent/KR20160023669A/ko not_active Withdrawn
- 2014-06-26 CN CN201480030666.XA patent/CN105307670A/zh active Pending
- 2014-06-26 PL PL14734003T patent/PL3013353T3/pl unknown
- 2014-06-26 HK HK16112683.9A patent/HK1224225A1/zh unknown
- 2014-06-26 EP EP14734003.8A patent/EP3013353B1/en active Active
- 2014-06-26 AU AU2014301631A patent/AU2014301631A1/en not_active Abandoned
- 2014-06-26 WO PCT/EP2014/001736 patent/WO2014206563A2/en not_active Ceased
- 2014-06-26 ES ES14734003T patent/ES2870085T3/es active Active
- 2014-06-26 EA EA201501080A patent/EA201501080A1/ru unknown
-
2015
- 2015-06-26 JP JP2016575155A patent/JP2017520571A/ja not_active Withdrawn
- 2015-06-26 MX MX2016017308A patent/MX2016017308A/es unknown
- 2015-06-26 BR BR112016029413A patent/BR112016029413A2/pt not_active IP Right Cessation
-
2019
- 2019-12-17 JP JP2019226998A patent/JP2020055866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520571A5 (enExample) | ||
| FI3985002T3 (fi) | Aryyli-, heteroaryyli- ja heterosyklisiä lääkeyhdisteitä sairauksien hoitoon | |
| JP2017520569A5 (enExample) | ||
| ES2892123T3 (es) | Derivados antivíricos de N4-hidroxicitidina | |
| AU2024219862A1 (en) | 4’-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| SA521422625B1 (ar) | مركبات بنزوثيادايازيبين واستخدامها كمعدلات لحمض الصفراء | |
| MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
| MX2009003768A (es) | Metodos, compuestos, composiciones y vehiculos para suministrar el acido 3-amino-1-propanosulfonico. | |
| HRP20230452T1 (hr) | Modulatori piruvat kinaze i njihova uporaba | |
| JPWO2020081450A5 (enExample) | ||
| AU2018360855A1 (en) | Modulators of the integrated stress pathway | |
| UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| JP2010509375A5 (enExample) | ||
| WO2017079195A1 (en) | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases | |
| JP2015535261A5 (enExample) | ||
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| MXPA06002069A (es) | Derivados de purina que inhiben la replicacion del vih. | |
| NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
| JP2017507987A (ja) | Ｔｃｏ複合体および治療薬の送達のための方法 | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| RU2005103226A (ru) | Новые соединения, составы и способы лечения воспалительных заболеваний и состояний | |
| TNSN07154A1 (en) | Purine derivatives for use as adenosin a-2a receptor agonists | |
| JP2017537886A5 (enExample) | ||
| JP2016508135A5 (enExample) |